Safety and Efficacy Study of TH-302 CNS Penetration in Recurrent High Grade Astrocytoma Following Bevacizumab

NCT01403610 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

HIGH GRADE GLIOMA

Interventions

DRUG: TH-302 preoperative
DRUG: Placebo
DRUG: TH-302 (escalating) with bevacizumab 10mg/kg

Sponsor

The University of Texas Health Science Center at San Antonio